[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647105":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":76,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Receive letermovir","EXPERIMENTAL","Participants will take letermovir",[13],"Drug: Letermovir",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Letermovir","1 tablet by mouth, once daily, for 84 days",[9],null,[22],{"name":23,"affiliation":5,"role":24},"David Al-Adra, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Office of Clinical Research Department of Surgery","CONTACT","608-576-0788","surgeryresearch@surgery.wisc.edu",{"name":32,"role":28,"phone":20,"phoneExt":20,"email":33},"Margaret R Jorgenson, PharmD","mjorgenson@uwhealth.org",[35],{"facility":36,"status":20,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":20},"University of Wisconsin - Madison","Madison","Wisconsin","53792","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-89.40123,43.07305,{"lat":46,"lon":45},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":53},"Merck Sharp & Dohme LLC","INDUSTRY","100647105","phase-4-letermovir-for-r-study-100647105",false,"NCT07706166","Letermovir for R+ Study","An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients","MISP CMV","Inclusion Criteria:\n\n* Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+\u002FR+ or D-\u002FR+)\n* Adults who received a kidney transplant, liver transplant, or any combination thereof\n\nExclusion Criteria:\n\n* Known contraindication to letermovir or its excipients\n* Current participation in another CMV related study\n* Unwilling or unable to participate in the study protocol","ALL","18 Years",{"count":65,"type":66},146,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.\n\nParticipants will take letermovir for 84 days.",[72,73],"Kidney Transplant","Liver Transplant",[75],"Moderate risk for CMV infection","NOT_YET_RECRUITING","2026-07-09",{"date":79,"type":80},"2026-07-15","ACTUAL",{"date":82,"type":66},"2026-08",{"date":84,"type":66},"2029-08",{"name":5,"class":6},1]